Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05DVP
|
||||
Former ID |
DAP000091
|
||||
Drug Name |
Zafirlukast
|
||||
Synonyms |
Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiasthmatic Agents
|
||||
Company |
AstraZeneca plc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C31H33N3O6S
|
||||
InChI |
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
|
||||
InChIKey |
YEEZWCHGZNKEEK-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 107753-78-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9415, 5366114, 7847477, 7980903, 8148198, 8153502, 11528636, 12014035, 14788829, 26719823, 26757966, 29224754, 46386595, 46506874, 48416705, 49681658, 53788583, 57322909, 75347132, 81041165, 81092894, 85209709, 92308342, 92308866, 93166425, 103183576, 103922131, 104219525, 104253269, 104310052, 117890551, 124659012, 124757391, 124893156, 124893157, 124893158, 124893159, 125164195, 125335352, 126616863, 126658431, 126665183, 127318333, 127318334, 127318335, 127318336, 127318337, 127318338, 127318339, 127318340
|
||||
ChEBI ID |
ChEBI:10100
|
||||
SuperDrug ATC ID |
R03DC01
|
||||
SuperDrug CAS ID |
cas=107753786
|
||||
Target and Pathway | |||||
Target(s) | Cysteinyl leukotriene receptor 1 | Target Info | Antagonist | [534965], [535660], [535666] | |
Pathway Interaction Database | Endothelins | ||||
References | |||||
Ref 534965 | Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc. 2000 Jan;100(1):32, 37-43. | ||||
Ref 540282 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3322). | ||||
Ref 534965 | Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc. 2000 Jan;100(1):32, 37-43. | ||||
Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
Ref 535666 | Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.